Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
MedImmune, the biologics arm of AstraZeneca, has entered a three-year research collaboration with the Clinical & Translational Science Institute at the University of California, San Francisco. The pact will focus on the institute’s Catalyst Awards program, which solicits applications from university scientists who want to move their research beyond the bench. The partners say they will work together to move the most promising research projects forward. MedImmune says the collaboration should benefit its R&D as well as AstraZeneca’s small-molecule drug discovery efforts.
This article has been sent to the following recipient: